Thomas Martyak
Interventional Cardiology · Fredericksburg, VANPI 1285621003
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,335 of the $66,386 with a category attached, or 86.4%. Amarin Pharma, Inc. accounts for 74.2% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $42,584 and has fallen 99.7% since, to $125 in 2024. Among interventional cardiology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $233.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$49K
- Bayer$14K
- Irhythm Technologies, Inc.$846
- Amgen$342
- Sanofi-aventis U.S. LLC$332
- AstraZeneca$328
- plus $2K from 26 others
Across 1 payment — averaging $700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$700
What the payments were for
- Speaking & faculty fees$57,33586%
- Travel & lodging$3,6055%
- Food & beverage$5,4398%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 96 | $49,277 |
| Bayer | 13 | $13,545 |
| Irhythm Technologies, Inc. | 24 | $846 |
| Amgen | 16 | $342 |
| Sanofi-aventis U.S. LLC | 23 | $332 |
| AstraZeneca | 20 | $328 |
| Esperion Therapeutics, Inc. | 8 | $182 |
| Johnson & Johnson | 13 | $169 |
| Boehringer Ingelheim | 7 | $163 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $150 |
| Actelion Pharmaceuticals US, Inc. | 6 | $142 |
| Portola Pharmaceuticals, LLC | 5 | $126 |
| Chiesi USA, Inc. | 1 | $104 |
| Novartis | 7 | $90 |
| Astellas Pharma US Inc | 5 | $89 |
| Abbott | 1 | $82 |
| AbbVie | 4 | $57 |
| Nuwellis, Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 4 | $54 |
| Cardiva Medical, Inc. | 2 | $37 |
| United Therapeutics Corporation | 2 | $30 |
| Pfizer | 2 | $26 |
| Medicomp Inc | 2 | $24 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Novo Nordisk | 1 | $19 |
| Merck | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Medtronic | 1 | $14 |
| Penumbra, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,386 in reported general payments places this provider in the 90th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Fredericksburg
- Rajiv TayalFredericksburg$984K
- Zeshan RanaFredericksburg$23K
- Clarence FindleyFredericksburg$19K
- Arijit ChandaFredericksburg$11K
- Deepak TalrejaVirginia Beach$1.5M
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.